Serum transforming growth factor-beta1 levels may have predictive and prognostic roles in patients with gastric cancer

Tumor Biology

Volumn 36, Issue 3, 2015, Pages 2097-2103

  Tas, Faruk ^a   Yasasever, Ceren Tilgen ^a   Karabulut, Senem ^a   Tastekin, Didem ^a   Duranyildiz, Derya ^a  

^a ISTANBUL UNIVERSITY   (Turkey)

Author keywords

Gastric cancer; Serum; TGF beta1

Indexed keywords

TRANSFORMING GROWTH FACTOR BETA1; TUMOR MARKER;

ADULT; AGED; BLOOD; CASE CONTROL STUDY; FEMALE; HUMAN; MALE; MIDDLE AGED; PREDICTIVE VALUE; PROGNOSIS; STOMACH NEOPLASMS; VERY ELDERLY;

ADULT; AGED; AGED, 80 AND OVER; CASE-CONTROL STUDIES; FEMALE; HUMANS; MALE; MIDDLE AGED; PREDICTIVE VALUE OF TESTS; PROGNOSIS; STOMACH NEOPLASMS; TRANSFORMING GROWTH FACTOR BETA1; TUMOR MARKERS, BIOLOGICAL;

EID: 84930883820     PISSN: 10104283     EISSN: 14230380     Source Type: Journal    
DOI: 10.1007/s13277-014-2817-9     Document Type: Article

References (14)

1. Vagenas K, Spyropoulos C, Gavala V, Tsamandas AC. TGFbeta1, TGFbeta2, and TGFbeta3 protein expression in gastric carcinomas: correlation with prognostic factors and patient survival. J Surg Res. 2007;139:182–8.
2. Ananiev J, Gulubova M, Tchernev G, Penkova M, Miteva R, Julianov A, et al. Relation between transforming growth factor-β1 expression, its receptor and clinicopathological factors and survival in HER-2 negative gastric cancers. Wien Klin Wochenschr. 2011;123:668–73.
3. Saito H, Tsujitani S, Oka S, Kondo A, Ikeguchi M, Maeta M, et al. The expression of transforming growth factor-1 is significantly correlated with the expression of vascular endothelial growth factor and poor prognosis of patients with advanced gastric carcinoma. Cancer. 1999;86:1455–62.
4. Hawinkels LJ, Verspaget HW, van Duijn W, van der Zon JM, Zuidwijk K, Kubben FJ, et al. Tissue level, activation and cellular localization of TGF-beta1 and association with survival in gastric cancer patients. Br J Cancer. 2007;97:398–404.
5. Kim JY, Jeon TJ, Bae BN, Kwon JE, Kim HJ, Park K, et al. The prognostic significance of growth factors and growth factor receptors in gastric adenocarcinoma. APMIS. 2012;121:95–104.
6. Maehara Y, Kakeji Y, Habashima A, Emi Y, Watanabe A, Akazawa K, et al. Role of transforming growth factor-β in invasion and metastasis in gastric carcinoma. J Clin Oncol. 1999;17:607–14.
7. Ma GF, Miao Q, Zeng XQ, Luo TC, Ma LL, Liu YM, et al. Transforming growth factor-β1 and -β2 in gastric precancer and cancer and roles in tumor-cell interactions with peripheral blood mononuclear cells in vitro. PLoS One. 2013;8:e54249.
8. Suda A, Saito N, Seshimo A, Kameoka S, Kobayashi M. Examination of transforming growth factor beta1 expression in the serum and tumor tissue of gastric cancer. Int Surg. 2009;94:182–8.
9. Saito H, Tsujitani S, Oka S, Kondo A, Ikeguchi M, Maeta M, et al. An elevated serum level of transforming growth factor-beta 1 (TGF-beta 1) significantly correlated with lymph node metastasis and poor prognosis in patients with gastric carcinoma. Anticancer Res. 2000;20:4489–93.
10. Niki M, Okajima K, Isozaki H, Toyoda M, Ichinona T, Nomura E, et al. Measurement of the plasma transforming growth factor-beta 1(TGF-beta 1) level in patients of gastric carcinoma-compared with the serum IAP level and the lymphocyte subsets (CD3, CD4, CD8). Nippon Shokakibyo Gakkai Zasshi. 1996;93:303–11.
11. Coban S, Yuksel O, Kockar MC, Koklu S, Basar O, Tutkak H, et al. The significance of serum transforming growth factor beta 1 in detecting of gastric and colon cancers. Hepatogastroenterology. 2007;54:1472–6.
12. Lin Y, Kikuchi S, Obata Y, Yagyu K. Serum levels of transforming growth factor β1 are significantly correlated with venous invasion in patients with gastric cancer. J Gastroenterol Hepatol. 2006;21:432–7.
13. Li X, Yue ZC, Zhang YY, Bai J, Meng X, Geng JS, et al. Elevated serum level and gene polymorphisms of TGF-β1 in gastric cancer. J Clin Lab Anal. 2008;22:164–71.
14. Yatsuya H, Toyoshima H, Tamakoshi K, Tamakoshi A, Kondo T, Hayakawa N, et al. Serum levels of insulin-like growth factor I, II, and binding protein 3, transforming growth factor beta-1, soluble fas ligand and superoxide dismutase activity in stomach cancer cases and their controls in the JACC Study. J Epidemiol. 2005;15 Suppl 2:S120–5.